Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic Stroke | Zendy

David A. Morrow | Zendy; Mark J. Alberts | Zendy; J.P. Mohr | Zendy; Sebastián F. Ameriso | Zendy; Marc P. Bonaca | Zendy; Shinya Goto | Zendy; Graeme J. Hankey | Zendy; Sabina A. Murphy | Zendy; Benjamin M. Scirica | Zendy; Eugene Braunwald | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic Stroke

Author(s) -

David A. Morrow,

Mark J. Alberts,

J.P. Mohr,

Sebastián F. Ameriso,

Marc P. Bonaca,

Shinya Goto,

Graeme J. Hankey,

Sabina A. Murphy,

Benjamin M. Scirica,

Eugene Braunwald

Publication year - 2013

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.111.000433

Subject(s) - medicine , stroke (engine) , hazard ratio , myocardial infarction , cardiology , placebo , confidence interval , pathology , mechanical engineering , alternative medicine , engineering

Vorapaxar is an antiplatelet agent that antagonizes thrombin-mediated activation of the protease-activated receptor-1 on platelets. We tested the efficacy and safety of vorapaxar in a prespecified analysis in the stroke subcohort from a multinational, randomized, placebo-controlled trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research